Therefore, we have investigated the combined effects of etoposide and MK2.III on p53 mutated cancer cells in vitro and in vivo as well as pharmacokinetics and bioavailability of MK2.III injected intraperitoneally and intravenously. Here, TP53 is linked to cancer.